TW201840337A - 使用ｈｓｐ９０抑制劑治療癌症的方法 - Google Patents

使用ｈｓｐ９０抑制劑治療癌症的方法 Download PDF

Info

Publication number
TW201840337A
TW201840337A TW107103636A TW107103636A TW201840337A TW 201840337 A TW201840337 A TW 201840337A TW 107103636 A TW107103636 A TW 107103636A TW 107103636 A TW107103636 A TW 107103636A TW 201840337 A TW201840337 A TW 201840337A
Authority
TW
Taiwan
Prior art keywords
cancer
bcl
inhibitor
lymphoma
hsp90
Prior art date
Application number
TW107103636A
Other languages
English (en)
Chinese (zh)
Inventor
尼爾 彼翰瑞
馬利蘭斯 赫南德茲
尚恩 藍德瑞特
天恩 余
喬納森Ｍ 羅斯貝格
翰睿 利辰斯登
Original Assignee
美商藍治療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商藍治療公司 filed Critical 美商藍治療公司
Publication of TW201840337A publication Critical patent/TW201840337A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW107103636A 2017-02-03 2018-02-01 使用ｈｓｐ９０抑制劑治療癌症的方法 TW201840337A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762454113P 2017-02-03 2017-02-03
US62/454,113 2017-02-03
US201762563991P 2017-09-27 2017-09-27
US62/563,991 2017-09-27
US201762587886P 2017-11-17 2017-11-17
US62/587,886 2017-11-17

Publications (1)

Publication Number Publication Date
TW201840337A true TW201840337A (zh) 2018-11-16

Family

ID=63038389

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107103636A TW201840337A (zh) 2017-02-03 2018-02-01 使用ｈｓｐ９０抑制劑治療癌症的方法

Country Status (13)

Country Link
US (2) US10799508B2 (enExample)
EP (1) EP3576794A1 (enExample)
JP (1) JP2020505433A (enExample)
KR (1) KR20190110128A (enExample)
CN (1) CN110536702A (enExample)
AU (1) AU2018215336A1 (enExample)
BR (1) BR112019016024A2 (enExample)
CA (1) CA3052594A1 (enExample)
IL (1) IL268430A (enExample)
MX (1) MX2019009227A (enExample)
RU (1) RU2019127350A (enExample)
TW (1) TW201840337A (enExample)
WO (1) WO2018144680A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020505433A (ja) 2017-02-03 2020-02-20 エイアイ・セラピューティクス・インコーポレーテッド Ｈｓｐ９０阻害剤を使用してがんを治療するための方法
BR112020006009A2 (pt) * 2017-09-27 2020-10-06 Al Therapeutics, Inc. métodos terapêuticos relacionados a inibidores de hsp90
BR112021007823A2 (pt) * 2018-11-08 2021-07-27 Glaxosmithkline Intellectual Property Development Limited combinação de inibidores da prmt5 e inibidores do bcl-2
AU2020214802A1 (en) 2019-01-29 2021-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
JP2022540317A (ja) * 2019-06-25 2022-09-15 ターベダ セラピューティクス インコーポレイテッド Ｈｓｐ９０結合コンジュゲートおよびその併用療法
PH12022551091A1 (en) 2019-11-05 2024-06-24 Abbvie Deutschland Dosing regimens for use in treating myelofibrosis and mpn-related disorders with navitoclax
WO2021157650A1 (ja) * 2020-02-05 2021-08-12 カルナバイオサイエンス株式会社 抗がん剤組成物
KR102683903B1 (ko) * 2020-09-16 2024-07-12 한국원자력의학원 아리피프라졸을 유효성분으로 함유하는 bcl2 저해제의 항암 효과 증진용 조성물
CN116615195A (zh) * 2020-09-17 2023-08-18 阿尔伯爱因斯坦医学院 使用bax激活剂的组合治疗
IL301322A (en) * 2020-09-17 2023-05-01 Albert Einstein College Medicine Combination therapy using bax activator agent
WO2023060137A2 (en) * 2021-10-05 2023-04-13 Board Of Regents, The University Of Texas System Methods and compositions comprising b7-h3 binding polypeptides
CN114588269B (zh) * 2022-04-06 2023-06-27 宁波大学附属人民医院 Bcl-2抑制剂和HDAC抑制剂的组合物及其用途
WO2024006292A2 (en) * 2022-06-27 2024-01-04 Foghorn Therapeutics Inc. Methods of treating cancer
CN115957328A (zh) * 2022-07-13 2023-04-14 杭州百可生物科技有限公司 一种用于治疗白血病的药物组合物以及白血病的治疗方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011060253A2 (en) 2009-11-13 2011-05-19 Myrexis, Inc. Methods of treating diseases, pharmaceutical compositions, and pharmaceutical dosage forms
CN103002895A (zh) * 2010-02-12 2013-03-27 尼基制药公司 治疗血液癌症的方法
WO2012148550A1 (en) 2011-02-25 2012-11-01 Myrexis, Inc. Prodrugs of therapeutic compounds
NZ618062A (en) * 2011-04-28 2016-04-29 Sloan Kettering Inst Cancer Hsp90 combination therapy
JP2020505433A (ja) 2017-02-03 2020-02-20 エイアイ・セラピューティクス・インコーポレーテッド Ｈｓｐ９０阻害剤を使用してがんを治療するための方法
BR112020006009A2 (pt) 2017-09-27 2020-10-06 Al Therapeutics, Inc. métodos terapêuticos relacionados a inibidores de hsp90

Also Published As

Publication number Publication date
RU2019127350A (ru) 2021-03-03
JP2020505433A (ja) 2020-02-20
WO2018144680A1 (en) 2018-08-09
KR20190110128A (ko) 2019-09-27
RU2019127350A3 (enExample) 2021-05-31
MX2019009227A (es) 2020-02-12
CN110536702A (zh) 2019-12-03
US20210030759A1 (en) 2021-02-04
CA3052594A1 (en) 2018-08-09
US10799508B2 (en) 2020-10-13
EP3576794A1 (en) 2019-12-11
IL268430A (en) 2019-09-26
US20180221376A1 (en) 2018-08-09
BR112019016024A2 (pt) 2020-03-31
AU2018215336A1 (en) 2019-09-12

Similar Documents

Publication Publication Date Title
US10799508B2 (en) Methods for treating cancer using HSP90 inhibitors
US20200253979A1 (en) Therapeutic methods relating to hsp90 inhibitors
US11266654B2 (en) Apilimod compositions and methods for using same
US20200138804A1 (en) Methods for treating cancer
JP7047148B2 (ja) 骨髄腫を治療するためのセルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）
TWI746449B (zh) 使用阿吡莫德治療癌症之方法
TWI841481B (zh) 乳酸鈣組成物及使用方法
CN107249638B (zh) 阿匹莫德用于治疗肾癌
JP2022537551A (ja) ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン
RU2739992C2 (ru) Композиции апилимода и способы их применения в лечении колоректального рака
CN112218658A (zh) 热量限制模拟物用于增强癌症治疗的化学免疫疗法的用途
WO2013059320A1 (en) Treatment of cancers with mutant npm1 with mek inhibitors
Savva 16th European Hematology Association Congress (Jun 9-12, 2011, London, UK)